公开(公告)号：US20230250174A1

公开(公告)日：2023-08-10

申请号：US18300248

申请日：2023-04-13

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/454 ,  A61K47/26 ,  A61K47/18 ,  A61K31/573

CPC classification number: C07K16/2818 ,  A61P35/00 ,  A61K31/454 ,  A61K47/26 ,  A61K47/183 ,  A61K31/573 ,  A61K45/06

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with lenalidomide and dexamethasone.

公开(公告)号：US20230136301A1

公开(公告)日：2023-05-04

申请号：US17979874

申请日：2022-11-03

Applicant: Janssen Biotech, Inc.

Inventor： Peter Hellemans ,  Ming Qi

IPC: C07K16/28 ,  A61K31/573 ,  A61P35/00

Abstract: This disclosure relates to methods of treating a hematologic malignancy, comprising administering to a subject a therapeutically effective amount of an anti-CD38 antibody and a corticosteroid for a time sufficient to treat the hematologic malignancy, wherein the dosing regimen includes a reduction, elimination, or reduction followed by elimination, of corticosteroid administration to the subject. This disclosure also relates to methods of treating a hematologic malignancy, comprising administering to a subject a therapeutically effective amount of an anti-CD38 antibody and a corticosteroid dose of

公开(公告)号：US20230295333A1

公开(公告)日：2023-09-21

申请号：US18300683

申请日：2023-04-14

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: C07K16/28 ,  A61K38/47 ,  A61K31/454 ,  A61K31/573 ,  A61K47/26 ,  A61K47/22 ,  A61P35/00 ,  A61K47/18

CPC classification number: C07K16/2896 ,  A61K38/47 ,  A61K31/454 ,  A61K31/573 ,  A61K47/26 ,  A61K47/22 ,  A61P35/00 ,  A61K47/183 ,  A61K2039/542

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with pomalidomide and dexamethasone.

公开(公告)号：US20230134748A1

公开(公告)日：2023-05-04

申请号：US17980149

申请日：2022-11-03

Applicant: Janssen Biotech, Inc.

Inventor： Peter Hellemans ,  Ming Qi

IPC: A61K39/395 ,  A61K31/573 ,  C07K16/28 ,  A61K38/47 ,  A61P35/00 ,  A61P7/00

Abstract: This disclosure relates to methods of treating a hematologic malignancy, comprising administering to a subject a therapeutically effective amount of an anti-CD38 antibody and a corticosteroid for a time sufficient to treat the hematologic malignancy, wherein the dosing regimen includes a reduction, elimination, or reduction followed by elimination, of corticosteroid administration to the subject. This disclosure also relates to methods of treating a hematologic malignancy, comprising administering to a subject a therapeutically effective amount of an anti-CD38 antibody and a corticosteroid dose of

公开(公告)号：US11618787B2

公开(公告)日：2023-04-04

申请号：US16177239

申请日：2018-10-31

Applicant: Janssen Biotech, Inc.

Inventor： Tahamtan Ahmadi ,  Christopher Chiu ,  Ming Qi ,  Amy Sasser ,  Jordan Schecter

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K31/573 ,  A61K31/495 ,  A61K31/4439 ,  A61K31/69 ,  A61K9/00 ,  A61K31/454 ,  A61K39/00

Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

公开(公告)号：US20230340145A1

公开(公告)日：2023-10-26

申请号：US18175345

申请日：2023-02-27

Applicant: Janssen Biotech, Inc.

Inventor： Tahamtan Ahmadi ,  Christopher Chiu ,  Ming Qi ,  Amy Sasser ,  Jordan Schecter

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/573 ,  A61K31/4439 ,  A61K31/69 ,  A61K39/395 ,  A61K9/00 ,  A61K31/454

CPC classification number: C07K16/2896 ,  A61P35/00 ,  A61K31/573 ,  A61K31/4439 ,  A61K31/69 ,  A61K39/3955 ,  A61K9/0019 ,  A61K31/454 ,  C07K2317/34 ,  C07K2317/565 ,  A61K2039/54

Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

公开(公告)号：US20230330224A1

公开(公告)日：2023-10-19

申请号：US18300288

申请日：2023-04-13

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: A61K9/00 ,  A61K39/395 ,  A61K31/573 ,  A61K31/69 ,  A61K38/47 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/573 ,  A61K31/69 ,  A61K38/47 ,  A61P35/00 ,  C12Y302/01035

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with bortezomib and dexamethasone.

公开(公告)号：US20200330593A1

公开(公告)日：2020-10-22

申请号：US16830909

申请日：2020-03-26

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: A61K39/395 ,  A61K38/47 ,  A61P35/00 ,  A61K9/00

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with bortezomib, melphalan and prednisone.

公开(公告)号：US20200308297A1

公开(公告)日：2020-10-01

申请号：US16830629

申请日：2020-03-26

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: C07K16/28 ,  A61K38/47 ,  A61K47/18 ,  A61K47/22 ,  A61K47/10 ,  A61K47/26 ,  A61P35/00 ,  C12N9/24

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and their uses.

公开(公告)号：US20230233676A1

公开(公告)日：2023-07-27

申请号：US18100056

申请日：2023-01-23

Applicant: Janssen Biotech, Inc.

Inventor： Ming Qi

IPC: A61K39/395 ,  A61P35/00 ,  A61K38/47 ,  A61K31/454 ,  A61K31/573 ,  G06Q30/06

CPC classification number: A61K39/39558 ,  A61P35/00 ,  A61K38/47 ,  C12Y302/01035 ,  A61K31/454 ,  A61K31/573 ,  G06Q30/06 ,  A61K2039/545

Abstract: The present invention relates to methods of treating multiple myeloma using an approved drug product comprising daratumumab and hyaluronidase in combination with pomalidomide and dexamethasone. Also described are methods for improving progression-free survival in multiple myeloma patients and methods of selling or offering for sale a drug product comprising daratumumab and hyaluronidase.